Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
